Keywords: درمان های هدفمند مولکولی; Chemotherapy; Antineoplastics; Anthracyclines; Taxanes; Molecular targeted therapies; Adverse effects; Heart failure; QTc prolongation; Tyrosine kinase inhibitors; Monoclonal antibodies; Cardio-oncology; Patient safety;